Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated Jun 03, 2025, titled "Sun Pharma Announces Top-Line Results from the Phase 2 Clinical Trials Evaluating SCD-044 for Moderate to Severe Psoriasis and Atopic Dermatitis".
SUNPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sun Pharma announced that its experimental drug SCD-044 failed to meet the primary endpoint in two separate Phase 2 clinical trials. The psoriasis trial involving 263 patients did not achieve the required 75% improvement in PASI score at Week 16. The atopic dermatitis trial with 250 patients also failed to meet its 75% EASI score improvement goal. The company has decided to discontinue all clinical development of SCD-044 and will evaluate next steps with its partner SPARC. No major safety issues were observed in either study, but the drug will not progress further in its current form.
This is a negative development for Sun Pharma's R&D pipeline as SCD-044 was an experimental candidate in inflammatory diseases. However, since the drug is not yet commercialized, there is no direct impact on current revenue or earnings. Investors may view this as a pipeline setback, though Sun Pharma's overall business remains diversified across specialty, generics, and consumer healthcare segments.